EVALUATING THE IMMUNOGENICITY OF HBV-C295 ISS CONJUGATE IN COMBINATION WITH HBV

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本实验的目的是评估一种新的HBV（B型肝炎病毒）结合疫苗在狒狒中的剂量反应。该实验将有助于确定向游离HBsAg中添加抗HBV Ag-C295 ISS缀合物是否可以增强对HBV表面抗原的免疫应答，以及用于增强狒狒免疫应答的缀合物的最佳剂量。这种新的HBV疫苗（HBV+ HBVIC）可以提高对HBV表面抗原的应答，

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objective of this experiment is to assess the dose response of a new conjugate HBV (hepatitis B virus) vaccine in baboons. This experiment will help determine if the addition of HBsAg-C295 ISS conjugate to free HBsAg can enhance the immune response to HBV surface antigen, and the optimal dose of conjugate for enhanced immune response in baboons. This new HBV vaccine (HBV+ HBsIC) may be beneficial to society since it could improve responses to HBV surface antig